Citations

Clear

6273 citation(s) found for "To, Andrew".

Collegiate women’s wrestling body fat percentage and minimum wrestling weight values: time for revisiting minimal body fat percent?
Oppliger, Robert A., Horswill, Craig A. , Dobbs, Ward C. , Fields, Jennifer B. , Cushard, Cliff, Rademacher, Paul , Jones, Margaret T. , Jagim, Andrew R , Tinsley, Grant M , Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | January 16, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1080/15502783.2024.2304561 | PMID 38226601 Get It

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans
Kottom, Theodore J. , Carmona, Eva M. , Limper, Andrew H. , Carmona, Eva M , Limper, Andrew H , Kottom, Theodore J

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 11, 2024 | Volume: 68 | Issue: 2 | Pages: No page available

10.1128/aac.00811-23 | PMID 38206037 Get It

ABSTRACT Pneumocystis jirovecii, the fungus that causes Pneumocystis jirovecii pneumonia (PJP), is a leading cause of morbidity and mortality in immunocompromised individuals. We have previously shown that lung epithelial cells can bind Pneumocystis spp. β-glucans via the EphA2 receptor, resulting in activation and release of proinflammatory cytokines. Herein, we show that in vivo Pneumocystis spp. β-glucans activation of the inflammatory signaling cascade in macrophages can be pharmacodynamically inhibited with the EphA2 receptor small-molecule inhibitor ALW-II-41-27. In vitro , when ALW-II-41-27 is administrated via intraperitoneal to mice prior to the administration of highly proinflammatory Saccharomyces cerevisiae β-glucans in the lung, a significant reduction in TNF-alpha release was noted in the ALW-II-41-27 pre-treated group. Taken together, our data suggest that targeting host lung macrophage activation via EphA2 receptor-fungal β-glucans interactions with ALW-II-41-27 or other EphA2 receptor kinase targeting inhibitors might be an attractive and viable strategy to reduce detrimental lung inflammation associated with PJP.
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe
Carrick, Richard , Marco, Corrado De , Gasperetti, Alessio , Bosman, Laurens P. , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Pendleton, Catherine, Tichnell, Crystal , Tandri, Harikrishna , Zeppenfeld, Katja , Wilde, Arthur A.M. , Davies, Brianna , Seifer, Colette , Roberts, Jason D. , MacIntyre, Ciorsti, Alqarawi, Wael , Cutler, Michael J. , Targetti, Mattia , Calò, Leonardo , Vitali, Francesco , Compagnucci, Paolo , Cappelletto, Chiara, Duru, Fırat , Jensen, Henrik Kjærulf , Svensson, Anneli , Dahlberg, Pia , Hasselberg, Nina E. , Marco, Andrea Di , Jordà, Paloma , Weidmann, Zoraida Moreno , Borowiec, Karolina , Delinière, Antoine , Tintelen, J. Peter van , Olivotto, Iacopo , Saguner, Ardan M. , Cox, Moniek G.P.J. , Merlo, Marco , Riele, Anneline S.J.M. te , Wu, Kathérine C. , Calkins, Hugh , James, Cynthia A. , Cadrin‐Tourigny, Julia , Carrick, Richard T , De Marco, Corrado , Gourraud, Jean-Baptiste , Trancuccio, Alessandro , Mazzanti, Andrea , Murray, Brittney , Zeppenfeld, Katja , Davies, Brianna , Alqarawi, Wael , Bertini, Matteo , Compagnucci, Paolo , Cappelletto, Chiara , Stolfo, Davide , Duru, Firat , Di Marco, Andrea , Arbelo, Elena , Delinière, Antoine , Saguner, Ardan M , Merlo, Marco , Krahn, Andrew D , Te Riele, Anneline S J M , Calkins, Hugh , James, Cynthia A , Cadrin-Tourigny, Julia , van Tintelen, J Peter , Olivotto, Iacopo , Jensen, Henrik Kjærulf , Gourraud, Jean‐Baptiste , Healey, Jeff S. , Tadros, Rafik , Casella, Michela , Russo, Antonio Dello , Luca, Antonio De , Arbelo, Elena , Biernacka, Elżbieta Katarzyna , Platonov, Pyotr G. , Haugaa, Kristina H. , Tondo, Claudio , Krahn, Andrew D.

Mayo Clinic

European Heart Journal | January 10, 2024 | Volume: 45 | Issue: 7 | Pages: 538-548

10.1093/eurheartj/ehad799 | PMID 38195003 Get It

Abstract Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (&lt;10%/5 years), intermediate- (10%–25%/5 years), and high-risk (&gt;25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. Results One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. Conclusions North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
Feasibility of using a transmission ion chamber for QA tests of medical linear accelerators
Farrokhkish, Makan, Veres, Andrew J., Santos, Luis E. Fong de los, DeMarco, John J., Islam, Mohammad K. , Fong de Los Santos, Luis E

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 9, 2024 | Volume: 25 | Issue: 2 | Pages: No page available

10.1002/acm2.14245 | PMID 38194595 Get It

AbstractPurposeTo study the feasibility of using the Integral Quality Monitoring (IQM) system for routine quality assurance (QA) of photon beams.MethodsThe IQM system is a commercially available dose delivery verification tool, which consists of a spatially sensitive large area transmission ion chamber, mounted on the Linac collimator, and a calculation algorithm to predict the signals in response to radiation beams. By comparing the measured and predicted signals the system verifies the accuracy of beam delivery. The ion chamber unit is a battery powered system including a dual‐electrometer, temperature and pressure sensors, and inclinometers. The feasibility of using the IQM system for routine QA tests was investigated by measuring constancy values of beam parameters, with specially designed tests fields, and comparing them with those determined by a conventional system.ResultsThe sensitivity of the beam output constancy measurements by the IQM system was found to agree with those measured by a Farmer type ion chamber placed in water phantoms to within 0.1% for typical daily output variation of ± 0.5% and ± 1%. The beam symmetry was measured with a 4 cm × 4 cm aperture at multiple off‐axis distances and was found to have a highly linear relationship with those measured in a water phantom scan for intentionally introduced asymmetry between ‐3% and +3%. The beam flatness was measured with a two‐field ratio method and was found to be linearly correlated with those measured by water phantom scan. The dosimetric equivalent of a picket fence test performed by the IQM system can serve as a constancy check of the multileaf collimator (MLC) bank positioning test.ConclusionsThe IQM system has been investigated for constancy measurements of various beam parameters for photon beams. The results suggest that the system can be used for most of the routine QA tests effectively and efficiently.
The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma
Laoruangroj, Chonlada , Atherton, Pamela J. , Wiseman, Gregory A., Ansell, Stephen M. , Schumacher, Peyton, Witzig, Thomas E. , Witzig, T.E. , Feldman, Andrew L.

Mayo Clinic

Leukemia & Lymphoma | January 8, 2024 | Volume: 65 | Issue: 3 | Pages: 333-338

10.1080/10428194.2023.2295792 | PMID 38189774 Get It

Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Goldsweig, Andrew M. , Deng, Yihong , Yao, Xiaoxi , Desai, Nihar R. , Cohen, David J. , Aronow, Herbert D. , Messé, Steven R. , Ross, Joseph S. , Lansky, Alexandra J. , Savitz, Samuel T. , Cohen, David Jonathan , Goldsweig, Andrew M , Yao, Xiaoxi , Ross, Joseph S , Aronow, Herbert D , Deng, Yihong

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 8, 2024 | Volume: 17 | Issue: 1 | Pages: No page available

10.1161/circoutcomes.123.010200 | PMID 38189127 Get It

BACKGROUND: Following regulatory approval, medical devices may be used “off-label.” Patent foramen ovale (PFO) closure is indicated to reduce recurrent stroke but has been proposed for other indications, including migraine, transient ischemic attack, and diving decompression illness. We sought to evaluate PFO closure rates and indications relative to the timing of regulatory approval and publication of key randomized trials. METHODS: We performed a retrospective cohort study using the OptumLabs Data Warehouse of US commercial insurance enrollees from 2006 to 2019. We quantified PFO closure among individuals with ≥2 years of preprocedure coverage to establish indications, classified hierarchically as stroke/systemic embolism, migraine, transient ischemia attack, or other. RESULTS: We identified 5315 patients undergoing PFO closure (51.8% female, 29.2%≥60 years old), which increased from 4.75 per 100 000 person-years in 2006 to 6.60 per 100 000 person-years in 2019. Patients aged ≥60 years accounted for 29.2% of closures. Procedure volumes corresponded weakly with supportive clinical publications and device approval. Among patients with PFO closure, 58.6% underwent closure for stroke/systemic embolism, 10.2% for transient ischemia attack, 8.8% for migraine, and 22.4% for other indications; 17.6% of patients had atrial fibrillation at baseline; and 11.9% developed atrial fibrillation postprocedure. Those aged ≥60 years and male were less likely to undergo closure for migraine than stroke/systemic embolism. CONCLUSIONS: From 2006 to 2019, PFO closure use was consistently low and corresponded weakly with clinical trial publications and regulatory status. Nearly half of patients underwent PFO closure for indications unapproved by the Food and Drug Administration. Regulators and payers should coordinate mechanisms to promote utilization for approved indications to ensure patient safety and should facilitate clinical trials for other possible indications.
Ursolic Acid Induces Beneficial Changes in Skeletal Muscle mRNA Expression and Increases Exercise Participation and Performance in Dogs with Age-Related Muscle Atrophy
Schreiber, Paul, Lopez, Jaime G , Taylor, Alan T., Judge, Andrew R. , Judge, Sarah M. , Rasmussen, Blake B. , Talley, John J., Rème, Christophe A., Adams, Christopher M. , Nicolas, Celine S , Judge, Andrew R , Rasmussen, Blake B , Adams, Christopher M , Judge, Sarah M , Ebert, Scott M. , Schreiber, Paul, Taylor, Alan T.

Mayo Clinic

Animals | January 8, 2024 | Volume: 14 | Issue: 2 | Pages: 186

10.3390/ani14020186 | PMID 38254356 Get It

Muscle atrophy and weakness are prevalent and debilitating conditions in dogs that cannot be reliably prevented or treated by current approaches. In non-canine species, the natural dietary compound ursolic acid inhibits molecular mechanisms of muscle atrophy, leading to improvements in muscle health. To begin to translate ursolic acid to canine health, we developed a novel ursolic acid dietary supplement for dogs and confirmed its safety and tolerability in dogs. We then conducted a randomized, placebo-controlled, proof-of-concept efficacy study in older beagles with age-related muscle atrophy, also known as sarcopenia. Animals received placebo or ursolic acid dietary supplements once a day for 60 days. To assess the study’s primary outcome, we biopsied the quadriceps muscle and quantified atrophy-associated mRNA expression. Additionally, to determine whether the molecular effects of ursolic acid might have functional correlates consistent with improvements in muscle health, we assessed secondary outcomes of exercise participation and T-maze performance. Importantly, in canine skeletal muscle, ursolic acid inhibited numerous mRNA expression changes that are known to promote muscle atrophy and weakness. Furthermore, ursolic acid significantly improved exercise participation and T-maze performance. These findings identify ursolic acid as a natural dietary compound that inhibits molecular mechanisms of muscle atrophy and improves functional performance in dogs.
What predicts the best 24-month outcomes following surgery for cervical spondylotic myelopathy? A QOD prospective registry study
Chan, Andrew K. , Park, Christine , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V. , Michalopoulos, Giorgos , Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | January 5, 2024 | Volume: 40 | Issue: 4 | Pages: 453-464

10.3171/2023.11.spine23222 | PMID 38181405 Get It

OBJECTIVE The aim of this study was to identify predictors of the best 24-month improvements in patients undergoing surgery for cervical spondylotic myelopathy (CSM). For this purpose, the authors leveraged a large prospective cohort of surgically treated patients with CSM to identify factors predicting the best outcomes for disability, quality of life, and functional status following surgery. METHODS This was a retrospective analysis of prospectively collected data. The Quality Outcomes Database (QOD) CSM dataset (1141 patients) at 14 top enrolling sites was used. Baseline and surgical characteristics were compared for those reporting the top and bottom 20th percentile 24-month Neck Disability Index (NDI), EuroQol-5D (EQ-5D), and modified Japanese Orthopaedic Association (mJOA) change scores. A multivariable logistic model was constructed and included candidate variables reaching p ≤ 0.20 on univariate analyses. Least important variables were removed in a stepwise manner to determine the significant predictors of the best outcomes (top 20th percentile) for 24-month NDI, EQ-5D, and mJOA change. RESULTS A total of 948 (83.1%) patients with 24-month follow-up were included in this study. For NDI, 204 (17.9%) had the best NDI outcome and 200 (17.5%) had the worst NDI outcome. Factors predicting the best NDI outcomes included symptom duration less than 12 months (OR 1.5, 95% CI 1.1–1.9; p = 0.01); procedure other than posterior fusion (OR 1.5, 95% CI 1.03–2.1; p = 0.03); higher preoperative visual analog scale neck pain score (OR 1.2, 95% CI 1.1–1.3; p < 0.001); and higher baseline NDI (OR 1.06, 95% CI 1.05–1.07; p < 0.001). For EQ-5D, 163 (14.3%) had the best EQ-5D outcome and 169 (14.8%) had the worst EQ-5D outcome. Factors predicting the best EQ-5D outcomes included arm pain–only complaints (compared to neck pain) (OR 1.9, 95% CI 1.3–2.9; p = 0.002) and lower baseline EQ-5D (OR 167.7 per unit lower, 95% CI 85.0–339.4; p < 0.001). For mJOA, 222 (19.5%) had the best mJOA outcome and 238 (20.9%) had the worst mJOA outcome. Factors predicting the best mJOA outcomes included lower BMI (OR 1.03 per unit lower, 95% CI 1.004–1.05; p = 0.02; cutoff value of ≤ 29.5 kg/m 2 ); arm pain–only complaints (compared to neck pain) (OR 1.7, 95% CI 1.1–2.5; p = 0.02); and lower baseline mJOA (OR 1.6 per unit lower, 95% CI 1.5–1.7; p < 0.001). CONCLUSIONS Compared to the worst outcomes for EQ-5D, the best outcomes were associated with patients with arm pain–only complaints. For mJOA, lower BMI and arm pain–only complaints portended the best outcomes. For NDI, those with the best outcomes had shorter symptom durations, higher preoperative neck pain scores, and less often underwent posterior spinal fusions. Given the positive impact of shorter symptom duration on outcomes, these data suggest that early surgery may be beneficial for patients with CSM.
Novel Left Ventricular Unloading Strategies in Patients on Peripheral Venoarterial Extracorporeal Membrane Oxygenation Support
Inglis, Sara S. , Rosenbaum, Andrew , Rizzo, Skylar A. , Yalamuri, Suraj , Spencer, Philip J. , Villavicencio, Mauricio A. , Rosenbaum, Andrew N , Anderson, Jason H. , Inglis, Sara S , Behfar, Atta

Mayo Clinic

ASAIO Journal | January 5, 2024 | Volume: 70 | Issue: 5 | Pages: 396-403

10.1097/mat.0000000000002136 | PMID 38181416 Get It

The purpose of this study was to evaluate left ventricular (LV) unloading strategies in patients supported with peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO). A retrospective review was conducted of all consecutive patients requiring VA-ECMO support for any indication, who underwent novel LV unloading strategies with either direct left atrial venoarterial (LAVA) cannulation or pulmonary artery venoarterial (PAVA) venting, in comparison to Impella and intra-aortic balloon pump (IABP). The primary outcome was successful bridge to transplant, LV assist device, or myocardial recovery. Forty-six patients (63% male, mean age 52.8 ± 17.6 years) were included. Fourteen patients (30%) underwent novel unloading with either LAVA or PAVA, 11 patients (24%) underwent IABP placement, and 21 patients (46%) underwent Impella insertion. In the novel LV unloading cohort, 10 patients (71%) survived to hospital discharge. Four patients (29%) were weaned from ECMO and eight patients (57%) underwent cardiac transplantation. Although a trend favoring cannula-based unloading for the primary outcome was noted, the cohort was too small for statistical significance (79% LAVA/PAVA, 57% Impella, 45% IABP; p = 0.21). However, probability of survival was greater in the LAVA/PAVA cohort compared to Impella and IABP (p < 0.05). Thus, we demonstrate the efficacy of LA and PA cannulation as an alternative LV unloading strategy for patients supported with peripheral VA-ECMO.